Cel Sci Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>CS</div>
CVM -- USA Stock  

USD 14.25  0.06  0.42%

Cel Sci Price to Book Value is relatively stable at the moment as compared to the past year. The company's current Price to Book Value is estimated at 71.54. Price to Sales Ratio is expected to hike to 505.12 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (19.1 M). Cel Sci is scheduled to announce its earnings tomorrow. While many fundamental traders are getting carried away by overanalyzing balance sheets and income statements, it is reasonable to summarize Cel Sci against its basic efficiency ratios. We will evaluate why recent Cel Sci price moves suggest a bounce in January. Cel Sci odds of financial distress is over 93 percent. Will stakeholders continue to be optimistic, or should we expect a sell-off in January?
Published over three weeks ago
View all stories for Cel Sci | View All Stories
Are stakeholders happy with Cel Sci (NYSEMKT:CVM) basic indicators?
We consider Cel Sci somewhat reliable. Cel Sci secures Sharpe Ratio (or Efficiency) of 0.0225, which signifies that the company had 0.0225% of return per unit of risk over the last month. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Cel Sci, which you can use to evaluate future volatility of the firm. Please confirm Cel Sci Risk Adjusted Performance of 0.0391, downside deviation of 4.24, and Mean Deviation of 3.68 to double-check if the risk estimate we provide is consistent with the expected return of 0.11%.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Cel Sci income statement, its balance sheet, and the statement of cash flows. Potential Cel Sci investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Cel Sci investors may use each financial statement separately, they are all related. The changes in Cel Sci's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cel Sci's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Cel Sci fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Cel Sci performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Cel Sci shares is the value that is considered the true value of the share. If the intrinsic value Cel Sci is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Cel Sci. Please read more on our fundamental analysis page.

Are Cel Sci Earnings Expected to grow?

The future earnings power of Cel Sci involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Cel Sci factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Cel Sci stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Cel Sci expected earnings.

How Cel Sci utilizes its cash?

To perform a cash flow analysis of Cel Sci, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cel Sci is receiving and how much cash it distributes out in a given period. The Cel Sci cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Cel Sci Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (18.95 Million)

Cel Sci Gross Profit

Cel Sci Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Cel Sci previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Cel Sci Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Another Deeper Perspective

The modest gains experienced by current holders of Cel Sci could raise concerns from stakeholders as the firm it trading at a share price of 12.74 on very low momentum in volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in November. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.74. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Cel Sci partners.

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cel Sci has an asset utilization ratio of 5.23 percent. This denotes that the company is making $0.0523 for each dollar of assets. An increasing asset utilization means that Cel Sci is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
8.8 M
Assets Non Current
18.7 M
Current Assets8.82 Million31.7
Assets Non Current18.72 Million67.29

Cel Sci has a fair chance to close above $12.99 mark in January

Cel Sci new semi deviation upsurges over 4.09. Cel Sci exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Cel Sci individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Cel Sci future systematic risk.

Our Takeaway on Cel Sci Investment

While some firms in the biotechnology industry are either recovering or due for a correction, Cel Sci may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Cel Sci valuation and our trade advice on Cel Sci is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cel Sci.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Cel Sci. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com